Harmony Biosciences (HRMY)

• Market cap: $1.88B
• 1 day: -2.62%
• 5 days: -3.48%
• 1 month: -16.27%
• 3 months: 1.02%
• 6 months: -15.91%
• Year to date: -6.06%
• 1 year: 9.32%
• 5 years: -11.59%
• 10 years: -11.59%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Employees: 268

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

163% more repeat investments, than reductions

Existing positions increased: 126 | Existing positions reduced: 48

142% more call options, than puts

Call options by funds: $4.24M | Put options by funds: $1.76M

64% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 25

6% more funds holding

Funds holding: 231 [Q3] → 245 (+14) [Q4]

4.49% more ownership

Funds ownership: 87.9% [Q3] → 92.39% (+4.49%) [Q4]

9% less capital invested

Capital invested by funds: $2B [Q3] → $1.81B (-$185M) [Q4]

33% less funds holding in top 10

Funds holding in top 10: 6 [Q3] → 4 (-2) [Q4]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $42 28% upside
• Avg. target: $54 66% upside
• High target: $70 114% upside

4 analyst ratings

• positive: 4 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Patrick Trucchio 23% 1-year accuracy 42 / 185 met price target	114% upside $70	Buy Maintained	27 Feb 2025
Needham Ami Fadia 30% 1-year accuracy 52 / 171 met price target	53% upside $50	Buy Reiterated	26 Feb 2025
Mizuho Graig Suvannavejh 38% 1-year accuracy 9 / 24 met price target	28% upside $42	Outperform Maintained	20 Feb 2025
Deutsche Bank David Hoang 39% 1-year accuracy 7 / 18 met price target	68% upside $55	Buy Initiated	11 Feb 2025